What question did this study set out to answer?

This research aims to understand how the architecture of NPM1-mutated acute myeloid leukemia affects prognosis and treatment strategies.

July 11, 2026Discover OncologyOpen Access

Leukemic architecture as a framework for risk stratification in NPM1-mutated acute myeloid leukemia

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial investigates risk stratification in NPM1-mutated AML, suggesting new prognostic frameworks for better treatment decisions.

This research aims to understand how the architecture of NPM1-mutated acute myeloid leukemia affects prognosis and treatment strategies.
Integrative transcriptomic and epigenomic studies to identify stemness-linked gene programs.
Single-cell and clonal architecture analyses to explore differentiation trajectories.
Large-scale sequencing studies to assess co-mutational patterns and allele frequencies.
Identified primitive phenotype in NPM1c AML is linked to poorer survival and higher relapse risk.
Diverse leukemic cell states highlight the need for an architecture-informed prognosis.
Evidence shows that epigenetic mutations often occur before NPM1c mutations in leukemic evolution.

Tarantini et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial investigates risk stratification in NPM1-mutated AML, suggesting new prognostic frameworks for better treatment decisions.